Mostrar el registro sencillo del ítem
Artículo
Adherence to interferon ß-1b treatment in patients with multiple sclerosis in Spain
dc.creator | Fernández Fernández, Óscar | |
dc.creator | Izquierdo Ayuso, Guillermo | |
dc.creator | Agüera, Javier | |
dc.creator | Millán Pascual, Jorge | |
dc.creator | Ramió i Torrentà, Lluis | |
dc.creator | Oliva Nacarino, Pedro | |
dc.creator | Argente, Javier | |
dc.creator | Berdei, Yasmina | |
dc.creator | Soler, José María | |
dc.creator | Carmona, Olga | |
dc.creator | Errea, Jose María | |
dc.creator | Farrés, Jordi | |
dc.date.accessioned | 2015-02-04T11:21:22Z | |
dc.date.available | 2015-02-04T11:21:22Z | |
dc.date.issued | 2012 | |
dc.identifier.issn | 1932-6203 | es |
dc.identifier.uri | http://hdl.handle.net/11441/18255 | |
dc.description.abstract | Background: Adherence to interferon b-1b (INFb-1b) therapy is essential to maximize the beneficial effects of treatment in multiple sclerosis (MS). For that reason, the main objectives of this study are to assess adherence to INFb-1b in patients suffering from MS in Spain, and to identify the factors responsible for adherence in routine clinical practice. Methodology/Principal Findings: This was an observational, retrospective, cross-sectional study including 120 Spanish patients with MS under INFb-1b treatment. Therapeutic adherence was assessed with Morisky-Green test and with the percentage of doses received. The proportion of adherent patients assessed by Morisky-Green test was 68.3%, being indicative of poor adherence. Nevertheless, the percentage of doses received, which was based on the number of injected medication, was 94.3%. The main reason for missing INFb-1b injections was forgetting some of the administrations (64%). Therefore, interventions that diminish forgetfulness might have a positive effect in the proportion of adherent patients and in the percentage of doses received. In addition, age and comorbidities had a significant effect in the number of doses injected per month, and should be considered in the management of adherence in MS patients. Conclusion/Significance: Among all the available methods for assessing adherence, the overall consumption of the intended dose has to be considered when addressing adherence. | es |
dc.language.iso | eng | es |
dc.relation.ispartof | PLoS ONE, 7 (5), 1-7. | es |
dc.rights | Atribución-NoComercial-SinDerivadas 4.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Adherence to interferon ß-1b treatment in patients with multiple sclerosis in Spain | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.journaltitle | PLoS ONE | es |
dc.publication.volumen | 7 | es |
dc.publication.issue | 5 | es |
dc.publication.initialPage | 1 | es |
dc.publication.endPage | 7 | es |
dc.identifier.idus | https://idus.us.es/xmlui/handle/11441/18255 |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Adherence_interferon.pdf | 90.30Kb | [PDF] | Ver/ | |